7Baggers
 HC Wainwright Issues Positive Estimate for Genelux Earnings  Defense World Mon, 10 Nov 2025 07:37:58 GMT
 Genelux Corp. (GNLX) Receives a Buy from Lake Street  The Globe and Mail Sun, 09 Nov 2025 05:07:42 GMT
 Genelux (GNLX) Projected to Post Earnings on Thursday  Defense World Thu, 06 Nov 2025 07:12:17 GMT
 genelux reports q3 eps (21c), consensus (21c)  TipRanks Thu, 06 Nov 2025 00:24:10 GMT
 Immuno-oncology firm Genelux's Q3 net loss beats expectations  MarketScreener Wed, 05 Nov 2025 08:00:00 GMT
 Genelux commits to lung cancer fight with Olvi-Vec immunotherapy  Traders Union Mon, 03 Nov 2025 08:00:00 GMT
 genelux (nasdaq:gnlx) trading up 3.4% - still a buy?  MarketBeat Sat, 01 Nov 2025 09:08:59 GMT
 genelux corporation (gnlx) analyst insights, price targets & recommendations  Yahoo! Finance Canada Sat, 01 Nov 2025 03:00:48 GMT
 Genelux initiated with a Buy at Titan Partners  TipRanks Fri, 31 Oct 2025 07:00:00 GMT
 genelux price target raised to $20 from $10 at maxim  MSN Thu, 30 Oct 2025 13:24:58 GMT
 We Think Genelux (NASDAQ:GNLX) Can Afford To Drive Business Growth  富途牛牛 Thu, 30 Oct 2025 07:00:00 GMT
 weekly research analysts’ ratings changes for genelux (gnlx)  Defense World Wed, 29 Oct 2025 05:29:12 GMT

Genelux Corp.
(NASDAQ:GNLX) 

GNLX stock logo

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac...

Founded: 2001
IPO Price: $6 (Jan 26, 2023)
Full Time Employees: 15
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends